NASDAQ:SPPI - Spectrum Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$14.34 -0.14 (-0.97 %)
(As of 10/17/2018 04:00 PM ET)
Previous Close$14.48
Today's Range$13.94 - $14.36
52-Week Range$13.59 - $25.29
Volume56,722 shs
Average Volume1.50 million shs
Market Capitalization$1.78 billion
P/E Ratio-13.30
Dividend YieldN/A
Beta1.88
Spectrum Pharmaceuticals, Inc. develops and commercializes oncology and hematology drug products. The company markets six drug products, including FUSILEV for patients with metastatic colorectal cancer and rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor for peripheral T-cell lymphoma (PTCL); ZEVALIN injection for patients with B-cell non-Hodgkin's lymphoma; MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ injection for PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients. It is also developing POZIOTINIB for treating breast and lung cancer; ROLONTIS for chemotherapy-induced neutropenia; and QAPZOLA for intravesical instillation in post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer. The company sells its drugs through group purchasing organizations, wholesalers, and directly in the United States; and through distributors in Europe. Spectrum Pharmaceuticals, Inc. has licensing and development agreement with Cell Therapeutics, Inc.; license agreement with Merck & Cie AG, Sloan-Kettering Institute, and Cydex Pharmaceuticals, Inc.; development and commercialization collaboration agreement with Allergan, Inc.; collaboration agreement with Nippon Kayaku Co., LTD.; licensing and collaboration agreement with Onxeo DK; and co-development and commercialization agreement with Hanmi Pharmaceutical Company. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Henderson, Nevada.

Receive SPPI News and Ratings via Email

Sign-up to receive the latest news and ratings for SPPI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:SPPI
CUSIP84763A10
Phone702-835-6300

Debt

Debt-to-Equity RatioN/A
Current Ratio3.28
Quick Ratio3.23

Price-To-Earnings

Trailing P/E Ratio-13.30
Forward P/E Ratio-14.78
P/E GrowthN/A

Sales & Book Value

Annual Sales$128.37 million
Price / Sales11.84
Cash FlowN/A
Price / CashN/A
Book Value$3.49 per share
Price / Book4.11

Profitability

EPS (Most Recent Fiscal Year)($1.07)
Net Income$-91,240,000.00
Net Margins-41.24%
Return on Equity-27.71%
Return on Assets-19.34%

Miscellaneous

Employees215
Outstanding Shares105,960,000
Market Cap$1.78 billion

Spectrum Pharmaceuticals (NASDAQ:SPPI) Frequently Asked Questions

What is Spectrum Pharmaceuticals' stock symbol?

Spectrum Pharmaceuticals trades on the NASDAQ under the ticker symbol "SPPI."

How were Spectrum Pharmaceuticals' earnings last quarter?

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) posted its earnings results on Thursday, August, 9th. The biotechnology company reported ($0.21) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.23) by $0.02. The biotechnology company earned $24.17 million during the quarter, compared to analyst estimates of $27.58 million. Spectrum Pharmaceuticals had a negative net margin of 41.24% and a negative return on equity of 27.71%. Spectrum Pharmaceuticals's revenue for the quarter was down 29.5% on a year-over-year basis. During the same period in the prior year, the business posted ($0.11) earnings per share. View Spectrum Pharmaceuticals' Earnings History.

When is Spectrum Pharmaceuticals' next earnings date?

Spectrum Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, November 1st 2018. View Earnings Estimates for Spectrum Pharmaceuticals.

What price target have analysts set for SPPI?

4 analysts have issued 12-month price objectives for Spectrum Pharmaceuticals' stock. Their forecasts range from $25.00 to $40.00. On average, they anticipate Spectrum Pharmaceuticals' share price to reach $33.00 in the next twelve months. This suggests a possible upside of 132.4% from the stock's current price. View Analyst Price Targets for Spectrum Pharmaceuticals.

What is the consensus analysts' recommendation for Spectrum Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spectrum Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Spectrum Pharmaceuticals.

Who are some of Spectrum Pharmaceuticals' key competitors?

Who are Spectrum Pharmaceuticals' key executives?

Spectrum Pharmaceuticals' management team includes the folowing people:
  • Mr. Joseph W. Turgeon, Pres, CEO & Director (Age 60)
  • Mr. Kurt A. Gustafson, Exec. VP & CFO (Age 50)
  • Mr. Thomas J. Riga, Exec. VP, COO & Chief Commercial Officer (Age 42)
  • Mr. Shivpreet Kapoor, VP of Strategic Planning & Investor Relations
  • Mr. Keith M. McGahan J.D., L.L.M., Sr. VP & Chief Legal Officer

Who are Spectrum Pharmaceuticals' major shareholders?

Spectrum Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Bank of Montreal Can (0.29%). Company insiders that own Spectrum Pharmaceuticals stock include Gilles Gagnon, Joseph W Turgeon, Keith M Mcgahan, Kurt A Gustafson, Rajesh C Md Shrotriya, Stuart Mitchell Krassner and Thomas J Riga. View Institutional Ownership Trends for Spectrum Pharmaceuticals.

Which major investors are buying Spectrum Pharmaceuticals stock?

SPPI stock was acquired by a variety of institutional investors in the last quarter, including Bank of Montreal Can. View Insider Buying and Selling for Spectrum Pharmaceuticals.

How do I buy shares of Spectrum Pharmaceuticals?

Shares of SPPI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Spectrum Pharmaceuticals' stock price today?

One share of SPPI stock can currently be purchased for approximately $14.20.

How big of a company is Spectrum Pharmaceuticals?

Spectrum Pharmaceuticals has a market capitalization of $1.78 billion and generates $128.37 million in revenue each year. The biotechnology company earns $-91,240,000.00 in net income (profit) each year or ($1.07) on an earnings per share basis. Spectrum Pharmaceuticals employs 215 workers across the globe.

What is Spectrum Pharmaceuticals' official website?

The official website for Spectrum Pharmaceuticals is http://www.sppirx.com.

How can I contact Spectrum Pharmaceuticals?

Spectrum Pharmaceuticals' mailing address is 11500 SOUTH EASTERN AVENUE SUITE 240, HENDERSON NV, 89052. The biotechnology company can be reached via phone at 702-835-6300 or via email at [email protected]


MarketBeat Community Rating for Spectrum Pharmaceuticals (NASDAQ SPPI)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  330 (Vote Outperform)
Underperform Votes:  232 (Vote Underperform)
Total Votes:  562
MarketBeat's community ratings are surveys of what our community members think about Spectrum Pharmaceuticals and other stocks. Vote "Outperform" if you believe SPPI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SPPI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel